ReviewFrontiers in oncology2020
Opportunities and Challenges of the Human Microbiome in Ovarian Cancer.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06962059 (Vaginal Metabolome Healthy Volunteers Study), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vaginal Metabolome Healthy Volunteers Study
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Microbial and Immune Landscape of Malignant Ascites: Insights from Gut, Bladder, and Ascitic Fluid Analyses.Cancers · 2025Article
- Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction.Molecular biotechnology · 2025Article
- Natural Compounds as Potential Therapeutics for Pancreatic Cancer: A Narrative Review.Current drug metabolism · 2025Review
- The Gut Microbiome in Aging and Ovarian Cancer.Aging and cancer · 2024Article
- Deciphering the Puzzle: Literature Insights onMicroorganisms · 2024Review
- Implications of the microbiome and metabolic intermediaries produced by bacteria in breast cancer.Genetics and molecular biology · 2024Article
- Microbial harmony in female reproductive health: exploring the impact of intestinal flora on ovarian function and disease pathogenesis.American journal of translational research · 2024Review
- Insights into the Microbial Composition of Intratumoral, Reproductive Tract, and Gut Microbiota in Ovarian Cancer Patients.Advances in experimental medicine and biology · 2024Review
- The role of gut microbiota in T cell immunity and immune mediated disorders.International journal of biological sciences · 2023Review
- Zengshengping improves lung cancer by regulating the intestinal barrier and intestinal microbiota.Frontiers in pharmacology · 2023Article
- The Gut Microbiome and Female Health.Biology · 2022Review
- Etiopathogenesis of ovarian cancer. An inflamm-aging entity?Gynecologic oncology reports · 2022Review
- Varied Composition and Underlying Mechanisms of Gut Microbiome in Neuroinflammation.Microorganisms · 2022Review
- Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.Precision clinical medicine · 2022Review
- Identifying distinctive tissue and fecal microbial signatures and the tumor-promoting effects of deoxycholic acid on breast cancer.Frontiers in cellular and infection microbiology · 2022Article
- Tumor microbiome - an integral part of the tumor microenvironment.Frontiers in oncology · 2022Review
- The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities.Current oncology reports · 2021Review
- The link among microbiota, epigenetics, and disease development.Environmental science and pollution research international · 2021Review
- The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.Molecular medicine (Cambridge, Mass.) · 2021Review
- A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most lethal malignancy among gynecological cancers worldwide. Most ovarian cancer patients are diagnosed at an advanced stage because of non-specific clinical symptoms. The human microbiome plays a crucial role in maintaining the normal physiological and pathological state of the body. With the development of technologies such as DNA and 16S rRNA sequencing, an increasing number of findings on the role of microbiome in cancers are being reported. Microbiome abnormalities are increasingly associated with diseases, including cancer development, and response to therapies. Some studies have shown the relationship between microbiome changes and ovarian cancer. However, the mechanisms underlying this relationship are not yet fully understood. Here, we summarize the key findings in this regard by focusing on estrogen metabolism and host recognition receptors in microorganisms and changes in the gut or pelvic microbiome in patients with ovarian cancer. We further discuss the potential of using the microbiome as a novel biomarker for cancers. We also highlight the possibility to use microorganisms as a treatment modality to enhance the immune system, activate anti-tumor response, mediate chemotherapy resistance, and ameliorate the adverse effects of the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.